Quantitative multiplex methylation-specific PCR

Details Quantitative multiplex methylation-specific PCR Quantitative multiplex methylation-specific PCR

2004-10-28

2011-11-22

Strzelecka, Teresa E (Department: 1637)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091200

Reexamination Certificate

active

08062849

ABSTRACT:
Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific PCR (QM-MSP), multiple genes can be quantitatively evaluated from samples usually yielding sufficient DNA for analyses of only 1 or 2 genes. DNA sequences isolated from the sample are simultaneously co-amplified in an initial multiplex round of PCR, and the methylation status of individual hypermethylation-prone gene promoter sequences is then determined separately or in multiplex using a real time PCR round that is methylation status-specific. Within genes of the panel, the level of promoter hypermethylation as well as the incidence of promoter hypermethylation can be determined and the level of genes in the panel can be scored cumulatively. The QM-MSP method is adaptable for high throughput automated technology.

REFERENCES:
patent: 2003/0143606 (2003-07-01), Olek et al.
patent: 2005/0089862 (2005-04-01), Therianos et al.
Eads et al., MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. (2000) 28: e32, i-viii.
Goessl et al., Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. (2000) 60: 5941-5945.
Olek et al., GenBank Accession No. AX344838. (2002).
Buck et al., Design strategies and performance of custom DNA sequencing primers. BioTechniques (1999) 27: 528-536.
Johnson et al. Plasma nucleic acids in the diagnosis and management of malignant diseases. Clin. Chem. (2002) 48:1186-1193.
Miyamoto et al. Diagnostic and therapeutic applications of epigenetics. Jpn. J. Clin. Oncol. (2005) 35:293-301.
Brock et al., “Prognostic Importance of Promoter Hypermethylation of Multiple Genes in Esophageal Adenocarcinoma”,Clinical Cancer Research, 9:2912-2919, Aug. 1, 2003.
Buller et al., “Validation of a Multiplex Methylation-Sensitive PCR Assay for the Diagnosis of Prader-Willi and Angelman's Syndromes”,Molecular Diagnosis, 5(3):239-243, 2000.
Burbee et al., “Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression”,Journal of the National Cancer Institute, 93(9):6910-699, May 2, 2001.
Dammann et al., “Hypermethylation of the CpG Island of Ras Association Domain Family 1A (RASSF1A), a Putative Tumor Suppressor Gene from the 3p21.3 Locus, Occurs in a Large Percentage of Human Breast Cancers”,Cancer Research, 61:3105-3109, Apr. 1, 2001.
Dhar et al., “Analysis of Normal Epithelial Cell Specific-1 (NES1)/Kallikrein 10 mRNA Expression by in Situ Hybrdization, a Novel Marker for Breast Cancer”,Clinical Cancer Research, 7:3393-3398, Nov. 2001.
Evron et al., “Detection of Breast Cancer Cells in Ductal Lavage Fluid by Methylation-specific PCR”,The Lancet, 357:1335-1336, Apr. 28, 2001.
Evron et al., “Loss of Cyclin D2 Expression in the Majority of Breast Cancers Is Associated with Promoter Hypermethylation”,Cancer Research, 61:2782-2787, Mar. 15, 2001.
Fackler et al., “DNA Methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and TWIST in In Situ and Invasive Lobular Breast Carcinoma”,Int J Cancer, 107:970-975, 2003.
Fackler et al., “Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer”,Cancer Res, 64:4442-4452, 2004.
Goyal et al., “The Role for NES1 Serine Protease as a Novel Tumor Suppressor”,Cancer Research, 58:4782-4786, Nov. 1, 1998.
Herman et al., “Methylation-Sepcific PCR: A Novel PCR Assay for Methylation Status of CpG Islands”,Proc. Natl. Acad. Sci., 93:9821-9826, Sep. 1996.
Kashiwaba et al., “Aberrations of the APC Gene in Primary Breast Carcinoma”,J. Cancer Res Clin Oncol, 120:727-731, 1994.
Krop et al., “HIN-1, a Putative Cytokine Highly Expressed in Normal But Not Cancerous Mammary Epithelial Cells”,PNAS, 98(17):9796-9801, Aug. 14, 2001.
Lehmann et al., “Quantiative Assessment of Promoter Hypermethylation During Breast Cancer Development”,American Journal of Pathology, 160(2):605-612, Feb. 2002.
Li et al., “CpG Methylation as a Basis for Breast Tumor-Specific Loss of NES1/Kallikrein 10 Expression”,Cancer Research, 61:8014-8021, Nov. 1, 2001.
Lo et al., “Quantitative Analysis of Aberrant p16 Methylation Using Real-Time Quantitative Methylation-Specific Polymerase Chain Reaction”,Cancer Research, 59:3899-3903, Aug. 15, 1999.
Palmisano et al., “Predicting Lung Cancer by Detecting Aberrant Promoter Methylation in Sputum”,Cancer Research, 60:5954-5958, Nov. 1, 2000.
Sarrio et al., “Epigenetic and Genetic Alternations of APC and CDH1 Genes in Lobular Breast Cancer: Relationships With Abnormal E-Cadherin and Catenin Expression and Microsatellite Instability”,Int. J. Cancer, 106:208-215, 2003.
Sirchia et al., “Endogenous Reactivation of the RARβ2 Tumor Suppressor Gene Epigenetically Silenced in Breast Cancer”,Cancer Research, 62:2455-2461, May 1, 2002.
Trinh et al., “DNA Methylation Analysis by MethyLight Technology”,Methods, 25:456-462, 2001.
Virmani et al., “Aberrant Methylation of the Adenomatous Polyposis Coli (APC) Gene Promoter 1A in Breast and Lung Carcinomas”,Clinical Cancer Research, 7:1998-2004, Jul. 2001.
Widschwendter et al., “Methylation and Silencing of the Retinoic Acid Receptor-β2 Gene in Breast Cancer”,Journal of the National Cancer Institute, 92(10):826-832, May 17, 2000.
Wong et al., “Quantiative Analysis of Tumor-Derived Methylated p16INK4a Sequences in Plasma, Serum and Blood Cells of Hepatocellular Carcinoma Subjects”,Clin Cancer Res, 9:1047-1052, 2003.
Yan et al., “Role of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer”,Journal of Mammary Gland Biology and Neoplasia, 6(2):183-192, 2001.
Yunes et al., “Loss of Expression of the Putative Tumor Suppressor NES1 Gene in Biospy-Proven Ductal Carcinoma In Situ Predicts For Invasive Carcinoma At Definitive Surgery”,Int. J. Radiation Oncology Biol. Phys., 56(3):653-657, 2003.
Eads et al., “MethylLight: a high-throughput assay to measure DNA methylation.”Nucleic Acids Res. 28(e28):i-viii (2000).
Goessl et al., “Fluorescent Methylation-specific Polymerase Chain Reaction for DNA-based Detection of Prostate Cancer in Bodily Fluids.”Cancer Res. 60:5941-5945 (2000).
Olek et al., GenBank Acession No. AX344838 (2002).

Affiliated with

Also associated with

Rating

Quantitative multiplex methylation-specific PCR does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quantitative multiplex methylation-specific PCR, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quantitative multiplex methylation-specific PCR will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4280842